{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:24:04Z","timestamp":1788445444049,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007903","name":"Bloodwise","doi-asserted-by":"publisher","award":["13028"],"award-info":[{"award-number":["13028"]}],"id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007903","name":"Bloodwise","doi-asserted-by":"publisher","award":["13028"],"award-info":[{"award-number":["13028"]}],"id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We previously demonstrated the in vitro killing of AML cells by the combination of the lipid-lowering agent bezafibrate (BEZ) and the contraceptive hormone medroxyprogesterone acetate (MPA). A phase II trial demonstrated in vivo safety and efficacy of BEZ and MPA (BaP) in elderly, relapsed\/refractory AML and high-risk myelodysplastic syndrome (MDS) patients. However, we observed dose-limiting toxicities in a second trial that attempted to improve outcomes via escalation of BaP doses. Thus we sought to identify a third repurposed drug that potentiates activity of low dose BaP (BaP 0.1\u2009mM).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and Results<\/jats:title>\n                <jats:p>We demonstrate that addition of a commonly used anti-epileptic, valproic acid (VAL) to low dose BaP (BaP 0.1\u2009mM)(VBaP) enhanced killing of AML cell lines\/primary AML cells to levels similar to high dose BaP (BaP 0.5\u2009mM). Similarly, addition of VAL to BaP 0.1\u2009mM enhanced reactive oxygen species (ROS), lipid peroxidation and inhibition of de novo fatty acid synthesis. Overexpression of Nrf2 in K562 and KG1a completely inhibited ROS production and rescued cells from VAL\/BaP 0.1\u2009mM\/VBaP killing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Given the good safety data of low-dose BaP in elderly\/relapsed\/refractory AML patients, and that VAL alone is well-tolerated, we propose VBaP as a novel therapeutic combination for AML.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-021-01570-z","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T11:06:48Z","timestamp":1634900808000},"page":"275-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing"],"prefix":"10.1038","volume":"126","author":[{"given":"Yao","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Southam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Trova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Beke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader","family":"Alhazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshul","family":"Radotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Drayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris M.","family":"Bunce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0034-6899","authenticated-orcid":false,"given":"Farhat L.","family":"Khanim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"1570_CR1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","volume":"27","author":"T Buechner","year":"2009","unstructured":"Buechner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Mueller-Tidow C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol. 2009;27:61\u20139.","journal-title":"J Clin Oncol"},{"key":"1570_CR2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.2009.22.9088","volume":"28","author":"AK Burnett","year":"2010","unstructured":"Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin M-F, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 Trial. J Clin Oncol. 2010;28:586\u201395.","journal-title":"J Clin Oncol"},{"key":"1570_CR3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB. Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Disco. 2004;3:673\u201383.","journal-title":"Nat Rev Drug Disco"},{"key":"1570_CR4","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","volume":"111","author":"ZY Wang","year":"2008","unstructured":"Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505\u201315.","journal-title":"Blood"},{"key":"1570_CR5","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","volume":"111","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008;111:3968\u201377.","journal-title":"Blood"},{"key":"1570_CR6","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1158\/0008-5472.CAN-15-0202","volume":"75","author":"AD Southam","year":"2015","unstructured":"Southam AD, Khanim FL, Hayden RE, Constantinou JK, Koczula KM, Michell RH, et al. Drug redeployment to kill leukemia and lymphoma cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids. Cancer Res. 2015;75:2530\u201340.","journal-title":"Cancer Res"},{"key":"1570_CR7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3109\/10428194.2014.939962","volume":"56","author":"RE Hayden","year":"2015","unstructured":"Hayden RE, Kussaibati R, Cronin LM, Pratt G, Roberts C, Drayson MT, et al. Bezafibrate and medroxyprogesterone acetate target resting and CD40L-stimulated primary marginal zone lymphoma and show promise in indolent B-cell non-Hodgkin lymphomas. Leuk Lymphoma. 2015;56:1079\u201387.","journal-title":"Leuk Lymphoma"},{"key":"1570_CR8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.12681","volume":"164","author":"E Molyneux","year":"2014","unstructured":"Molyneux E, Merrick B, Khanim FL, Banda K, Dunn JA, Iqbal G, et al. Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2 study (ISRCTN34303497). Br J Haematol. 2014;164:888\u201390.","journal-title":"Br J Haematol"},{"key":"1570_CR9","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3324\/haematol.2010.027821","volume":"95","author":"RE Hayden","year":"2010","unstructured":"Hayden RE, Pratt G, Drayson MT, Bunce CM. Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance. Haematologica. 2010;95:1889\u201396.","journal-title":"Haematologica."},{"key":"1570_CR10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2141.2009.08055.x","volume":"149","author":"JA Murray","year":"2010","unstructured":"Murray JA, Khanim FL, Hayden RE, Craddock CF, Holyoake TL, Jackson N, et al. Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). Br J Haematol. 2010;149:65\u20139.","journal-title":"Br J Haematol"},{"key":"1570_CR11","doi-asserted-by":"crossref","first-page":"e8147","DOI":"10.1371\/journal.pone.0008147","volume":"4","author":"FL Khanim","year":"2009","unstructured":"Khanim FL, Hayden RE, Birtwistle J, Lodi A, Tiziani S, Davies NJ, et al. Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. PLoS ONE. 2009;4:e8147.","journal-title":"PLoS ONE"},{"key":"1570_CR12","doi-asserted-by":"crossref","first-page":"100361","DOI":"10.1016\/j.conctc.2019.100361","volume":"14","author":"J Murray","year":"2019","unstructured":"Murray J, Pratt G, Jacob A, Clark F, Blundred R, Fox S, et al. Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers. Contemp Clin Trials Commun. 2019;14:100361.","journal-title":"Contemp Clin Trials Commun"},{"key":"1570_CR13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1189\/jlb.0113006","volume":"94","author":"F Zhou","year":"2013","unstructured":"Zhou F, Shen Q, Claret FX. Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. J Leukoc Biol. 2013;94:423\u20139.","journal-title":"J Leukoc Biol"},{"key":"1570_CR14","doi-asserted-by":"crossref","unstructured":"Sillar JR, Germon ZP, DeIuliis GN, Dun MD. The role of reactive oxygen species in acute myeloid leukaemia. Int J Mol Sci. 2019;20:6003.","DOI":"10.3390\/ijms20236003"},{"key":"1570_CR15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.tem.2017.10.003","volume":"28","author":"AL AM","year":"2017","unstructured":"AM AL, Syed DN, Ntambi JM. Insights into stearoyl-CoA desaturase-1 regulation of systemic metabolism. Trends Endocrinol Metab. 2017;28:831\u201342.","journal-title":"Trends Endocrinol Metab"},{"key":"1570_CR16","doi-asserted-by":"crossref","first-page":"6746","DOI":"10.1158\/0008-5472.CAN-17-0930","volume":"77","author":"O Abu Aboud","year":"2017","unstructured":"Abu Aboud O, Habib SL, Trott J, Stewart B, Liang S, Chaudhari AJ, et al. Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging. Cancer Res. 2017;77:6746\u201358.","journal-title":"Cancer Res"},{"key":"1570_CR17","doi-asserted-by":"crossref","first-page":"28479","DOI":"10.1074\/jbc.M303984200","volume":"278","author":"L Gao","year":"2003","unstructured":"Gao L, Zackert WE, Hasford JJ, Danekis ME, Milne GL, Remmert C, et al. Formation of prostaglandins E2 and D2 via the isoprostane pathway: a mechanism for the generation of bioactive prostaglandins independent of cyclooxygenase. J Biol Chem. 2003;278:28479\u201389.","journal-title":"J Biol Chem"},{"key":"1570_CR18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mrfmmm.2008.12.010","volume":"662","author":"J Birtwistle","year":"2009","unstructured":"Birtwistle J, Hayden RE, Khanim FL, Green RM, Pearce C, Davies NJ, et al. The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. Mutat Res. 2009;662:67\u201374.","journal-title":"Mutat Res"},{"key":"1570_CR19","doi-asserted-by":"crossref","first-page":"15266","DOI":"10.1016\/S0021-9258(18)95730-3","volume":"260","author":"TM Penning","year":"1985","unstructured":"Penning TM, Sharp RB, Krieger NR. Purification and properties of 3 alpha-hydroxysteroid dehydrogenase from rat brain cytosol. Inhibition by nonsteroidal anti-inflammatory drugs and progestins. J Biol Chem. 1985;260:15266\u201372.","journal-title":"J Biol Chem"},{"key":"1570_CR20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/leu.2008.283","volume":"23","author":"RE Hayden","year":"2009","unstructured":"Hayden RE, Pratt G, Davies NJ, Khanim FL, Birtwistle J, Delgado J, et al. Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2. Leukemia 2009;23:292\u2013304.","journal-title":"Leukemia"},{"key":"1570_CR21","doi-asserted-by":"crossref","unstructured":"Scher JU, Pillinger MH. 15d-PGJ2: the anti-inflammatory prostaglandin? Clin Immunol. 2005;114:100\u20139.","DOI":"10.1016\/j.clim.2004.09.008"},{"key":"1570_CR22","doi-asserted-by":"crossref","first-page":"10459","DOI":"10.1074\/jbc.M110314200","volume":"277","author":"T Shibata","year":"2002","unstructured":"Shibata T, Kondo M, Osawa T, Shibata N, Kobayashi M, Uchida K. 15-deoxy-delta 12,14-prostaglandin J2. a prostaglandin D2 metabolite generated during inflammatory processes. J Biol Chem. 2002;277:10459\u201366.","journal-title":"J Biol Chem"},{"key":"1570_CR23","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1021\/bi800199z","volume":"47","author":"Y Kusano","year":"2008","unstructured":"Kusano Y, Horie S, Shibata T, Satsu H, Shimizu M, Hitomi E, et al. Keap1 regulates the constitutive expression of GST A1 during differentiation of Caco-2 cells. Biochemistry 2008;47:6169\u201377.","journal-title":"Biochemistry"},{"key":"1570_CR24","doi-asserted-by":"crossref","unstructured":"Gronningsaeter IS, Fredly HK, Gjertsen BT, Hatfield KJ, Bruserud O. Systemic metabolomic profiling of acute myeloid leukemia patients before and during disease-stabilizing treatment based on all-trans retinoic acid, valproic acid, and low-dose chemotherapy. Cells. 2019;8:1229.","DOI":"10.3390\/cells8101229"},{"key":"1570_CR25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1042\/BJ20131476","volume":"459","author":"M Yuyama","year":"2014","unstructured":"Yuyama M, Fujimori K. Suppression of adipogenesis by valproic acid through repression of USF1-activated fatty acid synthesis in adipocytes. Biochem J. 2014;459:489\u2013503.","journal-title":"Biochem J"},{"key":"1570_CR26","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2013-04-491944","volume":"122","author":"PS Hole","year":"2013","unstructured":"Hole PS, Zabkiewicz J, Munje C, Newton Z, Pearn L, White P, et al. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood 2013;122:3322\u201330.","journal-title":"Blood"},{"key":"1570_CR27","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1182\/blood-2012-04-422121","volume":"120","author":"SA Rushworth","year":"2012","unstructured":"Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-kappaB and underlies its chemo-resistance. Blood 2012;120:5188\u201398.","journal-title":"Blood"},{"key":"1570_CR28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.clinbiochem.2017.05.018","volume":"50","author":"D Ivars","year":"2017","unstructured":"Ivars D, Orero MT, Javier K, Diaz-Vico L, Garcia-Gimenez JL, Mena S, et al. Oxidative imbalance in low\/intermediate-1-risk myelodysplastic syndrome patients: the influence of iron overload. Clin Biochem. 2017;50:911\u20137.","journal-title":"Clin Biochem"},{"key":"1570_CR29","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1136\/jim-2018-000953","volume":"67","author":"L Huang","year":"2019","unstructured":"Huang L, Liu Z, Jiang H, Li L, Fu R. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis. J Investig Med. 2019;67:1067\u201375.","journal-title":"J Investig Med"},{"key":"1570_CR30","doi-asserted-by":"crossref","first-page":"658","DOI":"10.18632\/oncotarget.321","volume":"2","author":"SA Heasman","year":"2011","unstructured":"Heasman SA, Zaitseva L, Bowles KM, Rushworth SA, Macewan DJ. Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. Oncotarget 2011;2:658\u201368.","journal-title":"Oncotarget"},{"key":"1570_CR31","doi-asserted-by":"crossref","unstructured":"Zimta AA, Cenariu D, Irimie A, Magdo L, Nabavi SM, Atanasov AG, et al. The role of Nrf2 activity in cancer development and progression. Cancers (Basel). 2019;11:1755.","DOI":"10.3390\/cancers11111755"},{"key":"1570_CR32","doi-asserted-by":"crossref","first-page":"e0177227","DOI":"10.1371\/journal.pone.0177227","volume":"12","author":"S Karathedath","year":"2017","unstructured":"Karathedath S, Rajamani BM, Musheer Aalam SM, Abraham A, Varatharajan S, Krishnamurthy P, et al. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. PLoS ONE. 2017;12:e0177227.","journal-title":"PLoS ONE"},{"key":"1570_CR33","volume":"7","author":"JI Yu","year":"2017","unstructured":"Yu JI, Choi C, Shin SW, Son A, Lee GH, Kim SY, et al. Valproic acid sensitizes hepatocellular carcinoma cells to proton therapy by suppressing NRF2 activation. Sci Rep. 2017;7:14986.","journal-title":"Sci Rep"},{"key":"1570_CR34","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3892\/mmr.2017.6621","volume":"16","author":"H Pan","year":"2017","unstructured":"Pan H, Wang H, Jia Y, Wang Q, Li L, Wu Q, et al. VPA and MEL induce apoptosis by inhibiting the Nrf2-ARE signaling pathway in TMZ-resistant U251 cells. Mol Med Rep. 2017;16:908\u201314.","journal-title":"Mol Med Rep"},{"key":"1570_CR35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.canlet.2015.12.016","volume":"372","author":"HY Cha","year":"2016","unstructured":"Cha HY, Lee BS, Chang JW, Park JK, Han JH, Kim YS, et al. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL. Cancer Lett. 2016;372:65\u201374.","journal-title":"Cancer Lett"},{"key":"1570_CR36","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2018-05-851824","volume":"132","author":"N Russell","year":"2018","unstructured":"Russell N, Burnett A, Hills R, Betteridge S, Dennis M, Jovanovic J, et al. Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. Blood. 2018;132:1452\u20134.","journal-title":"Blood."},{"key":"1570_CR37","volume":"19","author":"X Li","year":"2019","unstructured":"Li X, Dong Y, Li Y, Ren R, Wu W, Zhu H, et al. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study. BMC Cancer. 2019;19:819.","journal-title":"BMC Cancer"},{"key":"1570_CR38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2147\/CEOR.S203482","volume":"11","author":"G Tremblay","year":"2019","unstructured":"Tremblay G, Westley T, Cappelleri JC, Arondekar B, Chan G, Bell TJ, et al. Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons. Clinicoecon. Outcomes Res. 2019;11:551\u201365.","journal-title":"Clinicoecon. Outcomes Res"},{"key":"1570_CR39","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/cncr.21589","volume":"104","author":"G Bug","year":"2005","unstructured":"Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer. 2005;104:2717\u201325.","journal-title":"Cancer."},{"key":"1570_CR40","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1182\/blood-2013-12-546283","volume":"123","author":"M Tassara","year":"2014","unstructured":"Tassara M, Dohner K, Brossart P, Held G, Gotze K, Horst HA, et al. Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. Blood. 2014;123:4027\u201336.","journal-title":"Blood."},{"key":"1570_CR41","first-page":"1529","volume":"31","author":"C Stapnes","year":"2007","unstructured":"Stapnes C, Ryningen A, Hatfield K, Oyan AM, Eide GE, Corbascio M, et al. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. Int J Oncol. 2007;31:1529\u201338.","journal-title":"Int J Oncol"},{"key":"1570_CR42","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2141.2008.07449.x","volume":"144","author":"FL Khanim","year":"2009","unstructured":"Khanim FL, Bradbury CA, Arrazi J, Hayden RE, Rye A, Basu S, et al. Elevated FOSB-expression; a potential marker of valproate sensitivity in AML. Br J Haematol. 2009;144:332\u201341.","journal-title":"Br J Haematol"},{"key":"1570_CR43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eplepsyres.2004.08.009","volume":"62","author":"AK Birnbaum","year":"2004","unstructured":"Birnbaum AK, Hardie NA, Conway JM, Bowers SE, Lackner TE, Graves NM, et al. Valproic acid doses, concentrations, and clearances in elderly nursing home residents. Epilepsy Res. 2004;62:157\u201362.","journal-title":"Epilepsy Res"},{"key":"1570_CR44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.jcp.0000088903.24613.2a","volume":"23","author":"S Felix","year":"2003","unstructured":"Felix S, Sproule BA, Hardy BG, Naranjo CA. Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. J Clin Psychopharmacol. 2003;23:471\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"1570_CR45","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.clml.2017.11.007","volume":"18","author":"PR Colunga-Pedraza","year":"2018","unstructured":"Colunga-Pedraza PR, Colunga-Pedraza JE, Garza-Ledezma MA, Jaime-Perez JC, Cantu-Rodriguez OG, Gutierrez-Aguirre CH, et al. Danazol as first-line therapy for myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2018;18:e109\u2013e13.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1570_CR46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","volume":"34","author":"M Rojo de la Vega","year":"2018","unstructured":"Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34:21\u201343.","journal-title":"Cancer Cell"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01570-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01570-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01570-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T08:28:02Z","timestamp":1642580882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01570-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"alternative-id":["1570"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01570-z","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]},"assertion":[{"value":"7 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Primary blood samples from AML patients and normal donors were obtained as surplus to diagnosis samples and from normal donors (REC numbers 12\/NW\/0742 and ERN_17-0065). Healthy donor blood was obtained after informed consent under University of Birmingham (UoB) local ethical approval ERN_17-0065.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}